RxDoctor Payments Data

Melanie Crane, MD

Internal Medicine · Riverside, CANPI 1083695456

Payments from drug & device makers

$567in general payments, 2019–2025

Across 29 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$97
  • AbbVie$84
  • Pfizer$78
  • Merck$61
  • GSK$51
  • Johnson & Johnson$49
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$567 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$78,519
Medicare patients
251
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide235$281,148
EliquisApixaban94$87,716
MounjaroTirzepatide54$65,165
FarxigaDapagliflozin Propanediol39$46,218
XareltoRivaroxaban46$43,328
JanuviaSitagliptin Phosphate24$30,776
WegovySemaglutide12$20,464
JardianceEmpagliflozin12$20,175
RybelsusSemaglutide14$19,900
LinzessLinaclotide16$17,277
TrulicityDulaglutide13$13,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,682
Spiriva HandihalerTiotropium Bromide16$9,600
Levothyroxine Sodium521$9,077
Atorvastatin Calcium704$8,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$42$321,512261 claims
PfizerEliquis, Premarin$78$93,332106 claims
Lilly USA, LLCMounjaro, Trulicity$12$79,11467 claims
AstraZenecaFarxiga, Symbicort$97$49,88951 claims
Johnson & JohnsonXarelto$49$43,32846 claims
MerckJanuvia$61$30,77624 claims
AbbVieLinzess, Synthroid$84$25,01691 claims
GSKTrelegy Ellipta$51$10,68212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →